S-1/A: Actuate Therapeutics Files Amendment for IPO, Citing Progress in Cancer Therapy Development

Actuate Therapeutics updates its S-1 filing, highlighting clinical trial advancements and plans for its lead drug, elraglusib, in treating metastatic pancreatic cancer and other malignancies.

Summary

• Actuate Therapeutics has filed an amendment to its S-1 registration statement for an initial public offering.
• The company is focused on developing therapies for difficult-to-treat cancers by inhibiting glycogen synthase kinase-3 (GSK-3).
• Their lead drug, elraglusib, is being evaluated in a Phase 2 trial for metastatic pancreatic cancer, with top-line results expected in Q1 2025.
• Preliminary analysis of interim data shows a median overall survival of 12.2 months in the elraglusib combination therapy arm versus 7.3 months in the control group.
• Elraglusib is also being explored for Ewing sarcoma and other pediatric cancers.
• The company plans to use the IPO proceeds to fund clinical trials, product development, and manufacturing.
• A Phase 1 study for an oral tablet form of elraglusib is planned, with potential Phase 2 studies in melanoma and colorectal cancer.
• The company has granted the underwriters an option to purchase up to an additional 833,333 shares of common stock.
• The company faces risks including operating losses, dependence on elraglusib, and competition from other pharmaceutical companies.
• The company plans to list its common stock on the Nasdaq Capital Market under the symbol ACTU.

Sentiment

Score: 7

Explanation: The document presents a cautiously optimistic view. While highlighting positive clinical data and future plans, it also acknowledges significant risks and uncertainties inherent in the biopharmaceutical industry, resulting in a moderately positive sentiment.

Positives

• Elraglusib has shown promising results in a Phase 2 trial for metastatic pancreatic cancer.
• The company has identified Ewing sarcoma as a potential second indication for elraglusib.
• An oral tablet form of elraglusib is being developed, potentially expanding its applications.
• The company has Fast Track and Orphan Drug Designations from the FDA for pancreatic cancer.
• The company has a research and development collaboration with Lantern Pharma to leverage their artificial intelligence platform.

Negatives

• The company has a limited operating history and has incurred significant operating losses since its inception.
• The company's financial condition raises substantial doubt as to its ability to continue as a going concern.
• The company currently depends entirely on the success of elraglusib, which is its only product candidate.
• Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes.
• The company may not be successful in its efforts to investigate elraglusib in additional indications.

Risks

• The company has a limited operating history and has incurred significant operating losses since its inception.
• The company's financial condition raises substantial doubt as to its ability to continue as a going concern.
• The company currently depends entirely on the success of elraglusib, which is its only product candidate.
• Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes.
• The company may not be successful in its efforts to investigate elraglusib in additional indications.
• Use of elraglusib or any future product candidates could be associated with side effects, adverse events or other properties or safety risks.
• The termination of third-party licenses could adversely affect the company's rights to important compounds or technologies.
• The company's current elraglusib drug substance (DS) manufacturer is in China, and it is unknown how current or future geopolitical relationships with China may affect the company's ability to obtain DS.
• The company relies on third parties to conduct its non-clinical studies and its clinical trials.
• If the company and its third-party licensors do not obtain and preserve protection for their respective intellectual property rights, their competitors may be able to take advantage of their development efforts to develop competing drugs.
• If the company loses key management leadership, and/or scientific personnel, and if they cannot recruit qualified employees or other significant personnel, they may experience program delays and increased compensation costs, and their business may be materially disrupted.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• Even if this offering is successful, the company will require substantial additional capital to finance their operations.
• Concentration of ownership by the company's principal stockholders limits the ability of others to influence the outcome of director elections and other transactions requiring stockholder approval.

Future Outlook

The company plans to advance clinical trials of elraglusib, explore strategic partnerships, and seek regulatory development incentives. They anticipate using IPO proceeds to fund ongoing trials and initiate new studies.

Management Comments

• Management believes that the blockade of GSK-3 signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity.
• Management believes that the ability to extend survival by even a few months would be considered meaningful in this patient population.
• Management expects that top line data will then be available in the first quarter of 2025 based on enrollment of the last patients in the study in February 2024.

Industry Context

The announcement reflects the ongoing efforts in the biopharmaceutical industry to develop targeted therapies for cancers with high unmet needs, particularly in pancreatic cancer, where survival rates remain low. The focus on GSK-3 inhibition represents a novel approach compared to traditional chemotherapy and may offer a new treatment option.

Comparison to Industry Standards

• The mOS of 9-11 months in patients with mPDAC is a benchmark for the industry.
• The mOS of 12.2 months in the elraglusib combination therapy arm versus 7.3 months in the GnP control group arm (HR=0.60; log-rank p=0.012) is a benchmark for the industry.
• The mOS of 11.1 months for NALIRIFOX, 11.2 months with FOLFIRINOX and 8.5-9.2 months with GnP respectively in the first-line setting are benchmarks for the industry.
• The ORR in the rEECur phase 3 trial of 21% for CT is a benchmark for the industry.

Related Party Transactions

• The company issued convertible promissory notes to Bios Clinical Opportunity Fund, LP, a fund affiliated with two members of the board of directors of the company and a majority shareholder.
• An affiliate of Newbridge Securities Corporation, an underwriter in this offering, has previously acted as a placement agent for Bios Partners, in raising capital for Bios Fund III, NT and QP, LP and related special purpose vehicle funds Bios Actuate Co-Invest II, LP, Bios ONL Co-Invest I, LP and Bios SIRPant Co-Invest I, LP (collectively, Bios Fund III Entities), managed by Bios Partners, LP, the largest shareholder of the Company.
• Newbridge served as placement agent for approximately $7.1 million of the Company's Series C financing between August 2022 and June 2023.

Stakeholder Impact

• Shareholders: Potential for increased value if elraglusib is successful, but also risk of dilution from future capital raises.
• Employees: Job security and potential for career growth if the company succeeds.
• Patients: Potential access to new and effective cancer therapies.
• Suppliers: Increased business opportunities if the company's development programs progress.
• Creditors: Increased creditworthiness if the company becomes profitable.

Next Steps

• Complete the ongoing Elraglusib Injection Phase 2 mPDAC trial (Actuate-1801 Part 3B).
• Complete the existing pediatric refractory cancer Phase 1 dose escalation trial and initiate and complete the Phase 2 portion of this study in patients with refractory Ewing sarcoma (Actuate-1902).
• Satisfy funding commitments for ongoing IIT studies for the use of Elraglusib Injection with other chemotherapy agents to treat mPDAC and a separate trial to treat recurrent salivary gland cancer.
• Finalize development plans and initiate and complete a Phase 1 dose escalation study for the Elraglusib Oral Tablet in patients with advanced, refractory solid cancer.
• Finalize development plans and initiate and enroll patients in a Phase 2 study in refractory metastatic melanoma (Actuate-2401).

Key Dates

Keywords

elraglusib, pancreatic cancer, GSK-3, clinical trials, biopharmaceutical, metastatic, Ewing sarcoma, FDA, IPO, oncology